AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02160574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Physiological Saline
Description: The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
Study NCT02160574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ZuraPrep without IPA
Description: Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
Study NCT04546945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CD56
Description: detection of CD56 by flow cytometry
Study NCT00580190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam
Description: tablet, 0.5 mg, single dose, only on Day 7 of the study
Study NCT00580190 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
Study NCT00580190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00572778
Description: solution, 500 mg, single dose, only on Day 7 of the study
Study NCT00230607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agalsidase beta
Description: Pharmaceutical form: powder for reconstitution Route of administration: intravenous
Study NCT02129400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time
Study NCT02129400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%
Study NCT00567294 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed education
Description: Mailed education materials on osteoporosis and medication use over a 1-year period
Study NCT00567294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone coaching program for patients
Description: A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
Study NCT00567294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication adherence alert program for doctors
Description: Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
Study NCT04906291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste use
Description: Brushing three times a day
Study NCT04906291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste use
Description: Brushing three times a day
Study NCT02974517 — intervention group
Intervention type: DEVICE
Intervention: EmbryoScope®
Description: The intervention is EmbryoScope® versus conventional incubators.
Study NCT00764647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program for family caregivers of frail elders
Description: Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
Study NCT02818569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Oral form
Study NCT02818569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Saline Placebo
Study NCT01695902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosert-20
Study NCT01695902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Study NCT04554979 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine Pill
Description: hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
Study NCT01074112 — intervention group
Intervention type: DEVICE
Intervention: EFAST exam
Description: Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
Study NCT01074112 — intervention group
Intervention type: DEVICE
Intervention: Pelvic Ultrasound
Description: Ultrasound view of the pelvis. including the bladder and uterus
Study NCT01074112 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound Guided Vascular Access
Description: Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
Study NCT01074112 — intervention group
Intervention type: DEVICE
Intervention: Focused Ultrasound Scan
Description: Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
Study NCT01074112 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Ultrasound
Description: Ultrasound views of the heart
Study NCT01154790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: 6 subjects: study drug 2 subjects: placebo
Study NCT01154790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 6 subjects: study drug 2 subjects: placebo
Study NCT01154790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 6 subjects: study drug 2 subjects: placebo
Study NCT01154790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 subjects: study drug 2 subjects: placebo
Study NCT01154790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 6 subjects: study drug 2 subjects: placebo
Study NCT01063868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol extended release (ER)
Description: 100, 150, 200, 250 mg twice daily for 52 weeks
Study NCT05565508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hasson's technique for laparoscopic access in group b
Description: Hasson's technique for laparoscopic access in group b
Study NCT02230137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message arm
Description: Text message sent before each injection of insulin
Study NCT01063868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone controlled release (CR)
Description: 20, 30, 40, 50 mg twice daily for 52 weeks
Study NCT00911222 — intervention group
Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional
Study NCT03506113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gram stain-guided antibiotic choice
Description: The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
Study NCT01964534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-007
Description: ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
Study NCT01831050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
Study NCT01831050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Oral Polio Vaccine (tOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
Study NCT01831050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
Study NCT01964534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
Study NCT01964534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m² IV /30min (day 1, day 8, day 15)
Study NCT01964534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simplified LV5FU2
Description: Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
Study NCT02695264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000 recording
Study NCT01831050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi-Pasteur IPV (Sanofi IPV)
Description: Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
Study NCT01831050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glaxo SmithKline IPV (GSK IPV)
Description: Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
Study NCT01831050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum Institute of India IPV (SII IPV)
Description: Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India \[SII\]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
Study NCT03844646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Intermittent use of a continuous glucose monitor (CGM)
Study NCT03844646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietitian
Description: Monthly meetings with a dietitian
Study NCT03844646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietitian
Description: Monthly meetings with a dietitian
Study NCT01949506 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study NCT00130598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)
Description: control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast.
Study NCT01835587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
Study NCT02639143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Study NCT02639143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02664558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ubenimex
Study NCT02664558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03506113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guidelines-based antibiotics choice
Description: Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
Study NCT01287767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A multidimensional support program
Description: Counseling, education and problem-solving in support group, ad hoc counseling
Study NCT03622216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradanicline
Description: Three different doses over the course of the study
Study NCT00910338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFMT with Extracorporeal Biofeedback
Description: Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~* Twice a week for the first 4 weeks~* Once a week for the next 8 weeks
Study NCT00147446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Stress Management
Description: Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
Study NCT00147446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait List Control
Description: Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
Study NCT00795314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
Study NCT00795314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol Tartrate
Description: Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
Study NCT01897402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test Vaccine
Description: NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
Study NCT01897402 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Licensed Vaccine
Description: Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
Study NCT03622216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bradanicline
Description: Three different doses over the course of the study
Study NCT03622216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Bradanicline
Study NCT03622216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for Bradanicline
Study NCT03820206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
Study NCT03820206 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cesarean section
Description: Lower segement transverse cesarean section
Study NCT03820206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Lower segement transverse cesarean section
Study NCT03935685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine (Remeron)
Description: Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
Study NCT05104086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound elastography
Description: strain ratio and resistivity index
Study NCT04674995 — intervention group
Intervention type: PROCEDURE
Intervention: Stent placement
Description: All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
Study NCT01815905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile program for occupational and speech therapy
Study NCT01815905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation therapy
Study NCT01596296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical foley catheter
Description: 16 French foley catheter insertion
Study NCT01596296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 10mg
Description: Dinoprostone vaginal insertion
Study NCT01594957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: Participants will receive a single oral dose of LCQ908
Study NCT00112359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI 75 mg three times a day (TID)
Study NCT00112359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times a day (TID)
Study NCT03205072 — intervention group
Intervention type: DEVICE
Intervention: Spy Glass DS
Description: The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
Study NCT00508469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)
Description: One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
Study NCT00508469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% eye drops
Description: One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
Study NCT00508469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.05% eye drops
Description: One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
Study NCT00508469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Travalert Dosing Aid
Description: Approved device used with study medication to record time of instillation and quantify dosing
Study NCT01895582 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: 4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)
Study NCT01362075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia
Description: 150 ml ropivacaine, of which 100 ml is with adrenalin
Study NCT01362075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene catheter
Description: 7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
Study NCT04363866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
Study NCT04363866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a pill that looks like the study drug but has no real medicine in it.
Study NCT00945269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV
Study NCT00945269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT04655898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]CC-90001
Description: Oral